CY1116111T1 - LOCAL COMPOSITION FOR RADICAL CARE TREATMENT - Google Patents
LOCAL COMPOSITION FOR RADICAL CARE TREATMENTInfo
- Publication number
- CY1116111T1 CY1116111T1 CY20151100254T CY151100254T CY1116111T1 CY 1116111 T1 CY1116111 T1 CY 1116111T1 CY 20151100254 T CY20151100254 T CY 20151100254T CY 151100254 T CY151100254 T CY 151100254T CY 1116111 T1 CY1116111 T1 CY 1116111T1
- Authority
- CY
- Cyprus
- Prior art keywords
- radical
- care treatment
- local composition
- treatment
- keratosis
- Prior art date
Links
- 206010020649 Hyperkeratosis Diseases 0.000 abstract 2
- 208000001126 Keratosis Diseases 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 229940042129 topical gel Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση σχετίζεται με μια τοπική σύνθεση γέλης η οποία περιέχει (α) μια δραστική ουσία για τη θεραπεία της ακτινικής κεράτωσης, (β) μια κερατολυτικά δραστική ουσία, (γ) έναν παράγοντα σχηματισμού γέλης και (δ) έναν οργανικό διαλύτη για χρήση στη θεραπεία της ακτινικής κεράτωσης.The invention relates to a topical gel composition comprising (a) an active substance for the treatment of radial keratosis, (b) a keratolytically active substance, (c) a gel forming agent and (d) an organic solvent for use in the treatment. of radial keratosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08012237A EP2143421A1 (en) | 2008-07-07 | 2008-07-07 | Topical composition for the treatment of actinic keratosis |
EP09776876.6A EP2315581B1 (en) | 2008-07-07 | 2009-06-29 | Topical composition for the treatment of actinic keratosis |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116111T1 true CY1116111T1 (en) | 2017-02-08 |
Family
ID=40039993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100254T CY1116111T1 (en) | 2008-07-07 | 2015-03-13 | LOCAL COMPOSITION FOR RADICAL CARE TREATMENT |
Country Status (32)
Country | Link |
---|---|
US (1) | US8569320B2 (en) |
EP (2) | EP2143421A1 (en) |
JP (2) | JP5654987B2 (en) |
KR (1) | KR101689898B1 (en) |
CN (2) | CN102088957A (en) |
AR (1) | AR072685A1 (en) |
AU (1) | AU2009267471B2 (en) |
BR (1) | BRPI0915439B8 (en) |
CA (1) | CA2729974A1 (en) |
CL (1) | CL2010001642A1 (en) |
CO (1) | CO6351710A2 (en) |
CY (1) | CY1116111T1 (en) |
DK (1) | DK2315581T3 (en) |
EA (1) | EA019533B1 (en) |
EC (1) | ECSP11010762A (en) |
ES (1) | ES2532948T3 (en) |
HK (1) | HK1154793A1 (en) |
HR (1) | HRP20150222T1 (en) |
IL (1) | IL210134A (en) |
ME (1) | ME02147B (en) |
MX (1) | MX2011000054A (en) |
MY (1) | MY158428A (en) |
NZ (1) | NZ590288A (en) |
PE (1) | PE20110330A1 (en) |
PL (1) | PL2315581T3 (en) |
PT (1) | PT2315581E (en) |
RS (1) | RS53887B1 (en) |
SI (1) | SI2315581T1 (en) |
TW (1) | TWI433692B (en) |
UA (1) | UA101044C2 (en) |
WO (1) | WO2010003568A1 (en) |
ZA (1) | ZA201100653B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5798561B2 (en) * | 2009-10-08 | 2015-10-21 | エムエスディー コンシューマー ケア, インコーポレイテッド | Low ether composition and delivery device |
JP5950528B2 (en) * | 2011-09-30 | 2016-07-13 | 小林製薬株式会社 | Film-forming external preparation |
US20140350120A1 (en) * | 2011-12-12 | 2014-11-27 | Leo Laboratories Limited | Topical composition comprising an ingenol derivative and an oily solvent |
NZ606177A (en) * | 2012-01-30 | 2014-03-28 | Dolorgiet Gmbh & Co Kg | Compositions for the treatment of actinic keratosis |
GB201222405D0 (en) * | 2012-12-12 | 2013-01-23 | Leo Lab Ltd | Gel compositions |
EP3174601A4 (en) | 2014-07-31 | 2018-01-10 | Sun Pharmaceutical Industries Ltd | Oral pharmaceutical composition of isotretinoin |
AU2015314287B2 (en) | 2014-09-12 | 2019-04-18 | UNION therapeutics A/S | Antibacterial use of halogenated salicylanilides |
GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
EP3319637B1 (en) * | 2015-07-10 | 2022-11-09 | Infectopharm Arzneimittel und Consilium GmbH | Use of potassium hydroxide in the treatment of actinic keratosis |
GB201604484D0 (en) * | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
BR112019018687A2 (en) | 2017-03-10 | 2020-04-07 | Athenex Inc | methods of treatment and / or prevention of actinic keratosis |
US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
US20220175769A1 (en) * | 2020-12-08 | 2022-06-09 | Ankh Life Sciences Limited | Method of treatment of actinic keratoses |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2802005A (en) | 1957-08-06 | S-eluorourace | ||
US4234599A (en) * | 1978-10-04 | 1980-11-18 | Scott Eugene J Van | Treatment of skin keratoses with α-hydroxy acids and related compounds |
US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
US5167649A (en) * | 1988-08-22 | 1992-12-01 | Zook Gerald P | Drug delivery system for the removal of dermal lesions |
US5093360A (en) * | 1989-04-07 | 1992-03-03 | Yu Ruey J | Retinal, derivatives and their therapeutic use |
GB9023701D0 (en) * | 1990-10-31 | 1990-12-12 | Efamol Holdings | Medical treatment |
JP3117502B2 (en) * | 1991-08-27 | 2000-12-18 | 株式会社資生堂 | External preparation for skin |
US5627187A (en) | 1995-04-12 | 1997-05-06 | Katz; Bruce E. | 5-FU for treating actinic kerotoses |
RU2197273C2 (en) * | 1996-06-20 | 2003-01-27 | Лавифарм С.А. | Plaster-type device for local application of anticomedones composition and method of manufacturing the same |
US5993787A (en) * | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
US5955097A (en) * | 1996-10-18 | 1999-09-21 | Virotex Corporation | Pharmaceutical preparation applicable to mucosal surfaces and body tissues |
US6462071B1 (en) * | 2000-03-02 | 2002-10-08 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
ES2223277B1 (en) * | 2003-06-19 | 2006-03-01 | Fernando Bouffard Fita | ANESTHETIC COMPOSITION FOR TOPICAL ADMINISTRATION. |
EP2977043A3 (en) * | 2003-08-25 | 2016-04-06 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
AU2005267396B2 (en) * | 2004-06-24 | 2009-09-17 | Idexx Laboratories, Inc. | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
US20070053984A1 (en) | 2005-03-03 | 2007-03-08 | Monique Spann-Wade | Topical gels compositions |
EP1890687B1 (en) * | 2005-06-14 | 2008-09-17 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Stable pharmaceutical gel of diclofenac sodium |
US7851431B2 (en) * | 2005-07-27 | 2010-12-14 | Prescription Dispensing Laboratories | Treatment of actinic keratoses with calcium channel blockers |
US20070264317A1 (en) * | 2006-05-15 | 2007-11-15 | Perrigo Israel Pharmaceuticals Ltd. | Imiquimod cream formulation |
WO2008047857A1 (en) * | 2006-10-18 | 2008-04-24 | Fujifilm Corporation | METHOD OF PRODUCING COMPOSITION COMPRISING HARDLY WATER-SOLUBLE COMPOUND ENCLOSED IN HYDROPHILIC MATRIX AND PREPARATION FOR EXTERNAL USE COMPRISING ANTICANCER AGENT OR DRUG HAVING OCTANOL/WATER PARTITION COEFFICIENT (Log P) OF -3.0 OR MORE BUT NOT MORE THAN 3.0 ENCLOSED IN HYDROPHILIC BASE |
-
2008
- 2008-07-07 EP EP08012237A patent/EP2143421A1/en not_active Withdrawn
-
2009
- 2009-06-29 EA EA201100020A patent/EA019533B1/en unknown
- 2009-06-29 MY MYPI2011000028A patent/MY158428A/en unknown
- 2009-06-29 CN CN2009801266635A patent/CN102088957A/en active Pending
- 2009-06-29 BR BRPI0915439A patent/BRPI0915439B8/en active IP Right Grant
- 2009-06-29 KR KR1020117002825A patent/KR101689898B1/en active IP Right Grant
- 2009-06-29 EP EP09776876.6A patent/EP2315581B1/en active Active
- 2009-06-29 AU AU2009267471A patent/AU2009267471B2/en active Active
- 2009-06-29 CN CN201510185320.3A patent/CN104825384A/en active Pending
- 2009-06-29 UA UAA201101405A patent/UA101044C2/en unknown
- 2009-06-29 CA CA2729974A patent/CA2729974A1/en not_active Abandoned
- 2009-06-29 JP JP2011516999A patent/JP5654987B2/en active Active
- 2009-06-29 ES ES09776876.6T patent/ES2532948T3/en active Active
- 2009-06-29 DK DK09776876T patent/DK2315581T3/en active
- 2009-06-29 SI SI200931142T patent/SI2315581T1/en unknown
- 2009-06-29 PE PE2010001215A patent/PE20110330A1/en not_active Application Discontinuation
- 2009-06-29 RS RS20150185A patent/RS53887B1/en unknown
- 2009-06-29 NZ NZ590288A patent/NZ590288A/en unknown
- 2009-06-29 ME MEP-2015-38A patent/ME02147B/en unknown
- 2009-06-29 PT PT97768766T patent/PT2315581E/en unknown
- 2009-06-29 WO PCT/EP2009/004682 patent/WO2010003568A1/en active Application Filing
- 2009-06-29 MX MX2011000054A patent/MX2011000054A/en active IP Right Grant
- 2009-06-29 PL PL09776876T patent/PL2315581T3/en unknown
- 2009-06-29 US US13/002,971 patent/US8569320B2/en active Active
- 2009-07-03 AR ARP090102493A patent/AR072685A1/en unknown
- 2009-07-06 TW TW098122756A patent/TWI433692B/en active
-
2010
- 2010-12-20 IL IL210134A patent/IL210134A/en active IP Right Grant
- 2010-12-30 CL CL2010001642A patent/CL2010001642A1/en unknown
-
2011
- 2011-01-17 EC ECSP11010762 patent/ECSP11010762A/en unknown
- 2011-01-26 ZA ZA2011/00653A patent/ZA201100653B/en unknown
- 2011-02-07 CO CO11013458A patent/CO6351710A2/en not_active Application Discontinuation
- 2011-08-29 HK HK11109094.3A patent/HK1154793A1/en unknown
-
2014
- 2014-10-16 JP JP2014211989A patent/JP2015038129A/en not_active Withdrawn
-
2015
- 2015-02-26 HR HRP20150222TT patent/HRP20150222T1/en unknown
- 2015-03-13 CY CY20151100254T patent/CY1116111T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116111T1 (en) | LOCAL COMPOSITION FOR RADICAL CARE TREATMENT | |
CY1120961T1 (en) | ORAL DOSAGE CONTAINERS INCLUDING ANTI-PETROLEUM PATENT AND ACID INHIBITOR | |
NO20080068L (en) | Topical ungual formulations | |
BRPI0414581C1 (en) | compound, pharmaceutical composition comprising said compound and use of said compound | |
CY1117615T1 (en) | THEIAZOLIS SULFONAMIDIS AND OXAZOLIS COMPOUNDS | |
NO20083780L (en) | Topical composition comprising an antibacterial substance | |
CY1116064T1 (en) | DDP Suspension Recommendations IV | |
MA32562B1 (en) | Organic compounds for wound healing | |
CY1116638T1 (en) | INTERDERATIVE THERAPEUTIC SYSTEM FOR ADMINISTRATION OF AN ACTIVE SUBSTANCE | |
UY31673A1 (en) | "UREA HETEROCYCLIC DERIVATIVES AND METHODS OF USE OF THE SAME-211" | |
ECSP109917A (en) | NEW DERIVATIVES OF AZABIFENILAMINOBENZOIC ACID | |
CL2009000393A1 (en) | Pharmaceutical composition comprising a) an activatable pharmaceutical agent, b) a plasmonic active agent; Useful for the treatment of cell proliferation disorders. | |
AR048878A1 (en) | TOPIC COMPOSITIONS OF METADONA AND METHODS FOR USE | |
CL2011000846A1 (en) | Heterocyclic Substituted Compounds; pharmaceutical composition; and its use for the treatment of hepatitis c. | |
CL2008002430A1 (en) | Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd. | |
CL2008001123A1 (en) | Compounds derived from lipoic acid; pharmaceutical formulation comprising it; and use in the treatment of cancer. | |
CL2008000442A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A CHITOSAN, A COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENT, AND A VOLATILE SOLVENT; AND ITS USE TO TREAT PSORIASIS, MICOSIS BETWEEN OTHER DISEASES. | |
CY1122115T1 (en) | N1-ACYL-5-FLUOROPYRIMIDINONE DERIVATIVES | |
BRPI0921519A8 (en) | Packaged solid sufentanil drug dosage form and method for preventing oxidative degradation of said dosage form | |
CL2009000727A1 (en) | Substituted n-hydroxy-3-phenylprop-2-enmide and n-hydroxy-3-phenylpropanamide derivative compounds; deacetylase enzyme inhibitors; its pharmaceutical composition; Useful in the treatment of cancer, tumors, psoriasis, Alzheimer's, among others. | |
UY31864A (en) | DERIVATIVES OF UREA HETERICÍCLICA AND METHODS OF USE OF THE SAME-332 | |
CY1116840T1 (en) | USE 24-NORUDCA | |
NO20083144L (en) | Bovine osteopontin formulations to improve the curing process | |
CL2011000722A1 (en) | Pharmaceutical composition in the form of storage stable ointment, comprising: a) a vitamin d compound, b) a corticosteroid and c) a substituted alkylamino compound, in a petrolatum vehicle that optionally contains mineral oil, tocopherol or a combination thereof; use in treatment of psoriasis. | |
CL2009000665A1 (en) | Pyrrolidinyl derived compounds; pharmaceutical composition comprising said compounds; and its use in the treatment of anxiety, depression or both. |